



Anne B. Tolstrup, Ph.D.

Owner of AbtBioConsult

+45 2566 3065

atolstrup@abtbtc.com

Profile

Anne B. Tolstrup, Ph.D., is an experienced biopharmaceutical industry professional with more than 25 years of involvement in the areas of biologics cell line and process development, genetics analyses, scale-up, process validation including process performance qualification (PPQ), clinical and commercial GMP manufacturing. She has extensive experience working with regulatory agencies, including FDA, EMA, and national agencies in Europe, both with respect to IND and BLA filings. Anne has supported more than 35 clients in various aspects of biologics drug development after she started her consultancy business including strategic support, CDMO collaborations, regulatory filings and technical due diligences.

Experience

AbtBioConsult, Hillerød, Denmark

2018-present

Owner/CEO

Global consulting in bioprocesses with special expertise in cell line development and upstream process development and manufacturing for early/late stage and commercial products. Very experienced both with pre-clinical and late-stage CMC development of Biologics, PPQ, audits and regulatory module 3 submissions (clinical and market applications) as well as CDMO selection and managing. Experienced with strategic organizational changes for biopharma companies entering the Biologics arena and with technical due diligences of Biologics assets and companies.

BioProcess Technology Consultants/BPTG BDO, Boston, MA, USA

2018-2019

Senior Consultant and Managing Director

Cell line development and manufacturing process consultant in the areas of bioprocess CMC development and manufacturing for early/late stage and commercial products. Technical due diligences and strategic support of companies entering the biologics field.

Biogen, Manufacturing Sciences, Hillerød, Denmark

2015-2018

Sr. Manager Process Management (2016-2018)

Sr. Manager Cell Culture (2015-2016)

Scientific ownership of Large Scale (15.000 L) GMP Drug Substance Manufacturing processes (USP and DSP) including Novel Biologics Entities (NBEs) and biosimilars. Responsibilities included Tech transfer, Scale-up, Next-generation technology implementation, PPQ execution, global partner collaborations, investigations, audits including PAIs.

	<p>Boehringer Ingelheim, Biberach an der Riß, Germany 2011-2015</p> <p><i>Director Cell Culture NBE/Biosimilars (2014-2015)</i> <i>Director Cell Culture CMB (2013-2015)</i> <i>Head of Cell Culture II (2011-2013)</i></p> <p>>50 internal and external biologics programs: Mabs/bispecifics/biosimilars. Accountable for Expression Vectors, Genetic Testing, Cell Line Development, Media Development, Upstream Process Development, Harvest, Tox Material and Tech Transfer to GMP. Line manager for up to 110 people.</p>	
	<p>Symphogen, Ballerup, Denmark 2003-2011</p> <p><i>Director, Antibody Expression</i></p> <p>Cell line and upstream process development for manufacturing of recombinant antibody mixtures. Design of regulatory strategy for approval of antibody mixtures in close contact with FDA/EMA</p>	
	<p>Inoxell, Horsholm, Denmark 2001-2003</p> <p><i>Director Molecular and Cellular Biology</i></p> <p>Intracellular target discovery based on retroviral peptide library screenings in mammalian cells</p>	
	<p>Pharmexa (former M&E Biotech), Horsholm, Denmark 1997-2001</p> <p><i>Project Manager</i></p> <p>Responsible for the CellScreen drug discovery program based on retroviral peptide libraries</p>	
	<p>M&E Biotech Copenhagen, Denmark: 1996-1997</p> <p><i>Research Scientist</i></p> <p>Molecular Biology, University of Aarhus, Denmark, 1994-1996</p> <p><i>Assistant professor</i></p>	
Education	<p>University of Aarhus, Aarhus, Denmark 1994</p> <p><i>Ph.D. Molecular and Cellular Biology</i></p> <p>The tryptophanyl-tRNA synthetase and the membrane protein p106. Characterization of two proteins regulated by interferons</p>	
	<p>University of Aarhus, Aarhus, Denmark 1992</p> <p><i>M.S. Molecular Biology and Immunology</i></p> <p>Characterization of an interferon-α inducible membrane protein.</p>	
Board Memberships	<p>Member of the Danish National Industrial PhD Evaluation Committee 2010-2011</p> <p>Board member, BRIC Biotech Research & Innovation Center, University of Copenhagen, DK 2011-2015</p>	

	Scientific Advisor for “eCHO Systems” (EU-funded program w/15 PhD grants)	2015-2019
	Committee member for Aftagerpanel for Molecular Biology and Molecular Medicine, Aarhus University, Denmark	2016-
	Danish National Biologics Facility, Industrial Advisory Board (chair)	2021-
	Danish Technical University (DTU) Bioengineering’s Advisory Board Member	2022-
<i>Professional Associations</i>	Censor for Master and PhD students, Aarhus University and Danish Technical University	2005-
	Member of European Society for Animal Cell Technology (ESACT)	2005-
	Adjunct Professorship at Systems Biology, DTU	2010-2015
	ESACT Executive Committee (XC) member; Secretary since 2022	2019-
	ESACT2022 Lisbon June 26-29, 2022, Scientific Committee member	2019-2022
	ESACT2019 Scientific Committee (SC) Chair and Organizing Committee (OC) member, May 5-8, 2019, Copenhagen, Denmark	2016-2019
	ESACT 2017 Scientific Committee member and session chair, May 14-17, 2017, Lausanne, Switzerland	2015-2017
	Teacher at ESACTs annual Animal Cell Technology course, Llafranc, Spain	2011-
	Member of American Chemical Society	2018-
	Synapse (life science connect students organization at Copenhagen University): Mentor	2020-
Scientific Oral Presentations	Udvikling og produktion af biologiske lægemidler – fra ide til patient. Presenter at UNF (Ungdommens Naturvidenskabelige Forening); Nov 13, 2020. Odder Gymnasium, Denmark and on-line.	
	Next-Generation Biomanufacturing Processes and the Use of Integrated Advanced Process Control Tools. Presented at The Bioprocessing Summit; Aug 13-17 2018. Boston, MA.	
	How to implement next generation high titer biologics manufacturing at a commercial scale. Presented at the ManuPharma conference, Nov 30-Dec 1 2016. Frankfurt, Germany	
	Biologics - What will pharma manufacturing processes, technologies and sites look like in 2030? Round-table chair at the ManuPharma conference, Nov 30-Dec 1 2016, Frankfurt, Germany	
	Taking advantage of bioinformatics and omics technology to optimize CHO host cell lines and bioprocesses for biopharmaceutical Production. Keynote speaker presentation at Japanese Association for Animal Cell Technology (JAACT), Nov 11-14, 2014, Kitakyushu, Japan	
	New Approaches to Expedite Cell Line Development – Use of FACS Sorting and a Single Round of Cloning. Presented at Cell Line Development and Engineering, Sept 8-10, 2014, Berkeley CA	

Systems biotechnology driven development of CHO expression host cell lines and biopharmaceutical production processes. Presented at Cell Culture Engineering May 4-9, 2014, Quebec City, Canada

Impact of High-Throughput Screening on Cell Line Development and Product Quality. Presented at Cell Line Development and Engineering, June 6-8 2012, San Francisco, CA

Cell Culture World, speaker and panel session, 26-28 Feb 2012, Munich, Germany

Cost-Efficient and Consistent Single-Batch Manufacturing of Antibody Mixtures. Presented at Bioprocessing Summit, Aug 24-25, 2011, Boston, MA

Cost-efficient development of recombinant antibody mixtures by single-batch manufacturing. Presented at Recombinant Protein Production (RPP 6), Feb 16-19, 2011, Vienna, Austria

3rd Annual Proteins Congress, speaker, Berlin, 2010

Therapeutic Antibodies Europe, speaker, London, 2010

Second-generation platform based on random integration for single-batch production of recombinant human polyclonal antibody. Presented at Cell Line Development and Engineering, 1-5 March 2010, Prague, Czech Republic

4th Biotechnology and Molecular Biology, speaker, DK 2009

Development of third generation antibody therapeutics: Recombinant human polyclonal antibody products. Presented at the Animal Cell Technology Industrial Platform (ACTIP) meeting, Nov 17-18, 2008, Cambridge, UK

Optimizing Cell Culture Development, speaker, Boston, USA 2008

Drug Discovery Summit, Montreux, speaker, Switzerland, 2008

A cell banking strategy for recombinant polyclonal antibody manufacturing. Presented at Cell Line Development and Engineering, 3-7 March 2008, Prague, Czech Republic

One-pot production of recombinant human polyclonal antibody drug product. Presented at the 8th PEACE conference, 16-20 Sept 2007, Angra dos Reis, Brazil

Production of recombinant human polyclonal antibodies against Rhesus-D in CHO Flp-In cells. Presented at 3rd Recombinant Protein Production Meeting, 11-14 Nov 2004, Tavira, Portugal

Publications

Anne B. Tolstrup, Steven I. Max, Denis Drapeau and Timothy S. Charlebois (2021): Cell Culture Process Validation including Cell Bank Qualification. Book chapter (37) in Handbook of Validation in Pharmaceutical Processes, 4th Edition, edited by James Agalloco, Phil DeSantis, Anthony Grilli, Anthony Pavell.

Anne B. Tolstrup (2019): ESACT 2019 conference report. BioTechniques, 22 Aug 2019.

Tastanova A, Schulz A, Folcher M, Tolstrup A, Puklowski A, Kaufmann H, Fussenegger M. (2016): Overexpression of YY1 increases the protein production in mammalian cells. J Biotechnol. **219**:72-85.

Jennifer D. Könitzer, Markus M. Müller, German LeParc, Martin Pauers, Jan Bechmann, Patrick Schulz, Jochen Schaub, Barbara Enenkel, Tobias Hildebrand, Martin Hampel, [Anne B. Tolstrup](#) (2015): A global RNAseq-driven analysis of CHO host and production cell lines reveals distinct differential expression patterns of genes contributing to recombinant antibody glycosylation. *Biotechnol J.*; **10**(9):1412-23

Lore Florin, Søren K Rasmussen, Torben P Frandsen and [Anne B. Tolstrup](#) (2014): Manufacturing of complex protein products. Book chapter in *Animal Cell Biotechnology* (Wagner/Hauser, Eds., Gruyter)

Anja Puklowski, Till Wenger, Simone Schatz, Jennifer Koenitzer, Jochen Schaub, Barbara Enenkel, Anurag Khetan, Hitto Kaufmann, [Anne B Tolstrup](#) (2013): BI-HEX-GlymaxX cells enable efficient production of next generation biomolecules with enhanced ADCC activity. *BMC Proc.* **7** (Suppl 6): P63

Michaela Strotbek, Lore Florin, Jennifer Koenitzer, [Anne Tolstrup](#), Hitto Kaufmann, Angelika Hausser, Monilola A. Olayioye (2013): Stable microRNA expression enhances therapeutic antibody productivity of Chinese hamster ovary cells. *Metab Eng.* **20**: 157-66.

Søren K. Rasmussen, Henrik Næsted, Christian Müller, [Anne B. Tolstrup](#), Torben P. Frandsen (2012): Recombinant antibody mixtures: production strategies and cost considerations (Review). *Arch Biochem Biophys.* **526**(2): 159-45.

Søren K. Rasmussen, Lars S. Nielsen, Christian Müller, Thomas Bouquin, Nina T. Mønster, Frank Nygaard, Dietmar Weilguny, Torben P. Frandsen, [Anne B. Tolstrup](#) (2011): Recombinant antibody mixtures, optimization of cell line generation and single-batch manufacturing processes. *BMC Proc.* **5** (suppl 8): O2

Torben P. Frandsen, Henrik Næsted, Søren K. Rasmussen, Peter Hauptig, Finn C. Wiberg, Lone Kjær Rasmussen, Anne Marie Valentin Jensen, Pia Persson, Margareta Wikén, Anders Engström, Yun Jiang, Susan J. Thorpe, Cecilia Förberg, and [Anne B. Tolstrup](#) (2011): Consistent manufacturing and quality control of a highly complex recombinant polyclonal antibody product for human therapeutic use. *Biotechnol Bioeng.* **108**(9): 2171-81.

Christina R. Andersen, Lars S. Nielsen, Alexandra Baer, [Anne B. Tolstrup](#) and Dietmar Weilguny (2011): Efficient expression from one CMV enhancer controlling two core promoters. *Mol Biotechnol.* **48**(2):128-37.

Lars S. Nielsen, Alexandra Baer, Christian Müller, Kristian Gregersen, Nina Terp Münster, Søren K. Rasmussen, Dietmar Weilguny and [Anne B. Tolstrup](#) (2010): Single-batch production of recombinant human polyclonal antibodies. *Mol Biotechnol* **45**:257-66.

Søren K. Rasmussen, Lone K. Rasmussen, Dietmar Weilguny and [Anne B. Tolstrup](#) (2007): Manufacture of recombinant polyclonal antibodies. *Biotechnology Letters*, **29**(6):845-52.

[Anne B. Tolstrup](#), Torben P. Frandsen and Søren Bregenholt (2006): Development of recombinant human polyclonal antibodies for the treatment of complex human diseases. *Expert Opinion on Biological Therapy*, **6**(9): 905-912.

Finn C. Wiberg, Søren K. Rasmussen, Torben P. Frandsen, Lone K. Rasmussen, Kaja Tengbjerg, Vincent W. Coljee, Jacqueline Sharon, Chiou-Ying Yang, Søren Bregenholt, Lars S. Nielsen, John S. Haurum, and Anne B. Tolstrup (2006): Production of target-specific recombinant human polyclonal antibodies in mammalian cells. *Biotechnology and Bioengineering* **94**(2):396-405.

Mark Howarth, A Williams, Anne B. Tolstrup, Tim Elliott (2004): Tapasin enhances MHC class I peptide presentation according to peptide half-life. *Proc Natl Acad Sci U S A.* **101**(32):11737-42.

Anne B. Tolstrup, Mogens Duch, Iben Dalum, Finn Skou Pedersen and Søren Mouritsen (2001): Functional screening of a retroviral peptide library for MHC class I presentation, *Gene*, **263**, 77-84.

Pedersen, F.S., Lund, A.H., Jespersen, T., Dalum, I., Tolstrup, A., Mouritsen, S., and Duch, M.: Retroviruses in animal cell biotechnology. Meeting report from China-EU Workshop: Applications of biotechnology to Health. 1997.

Anne B. Tolstrup, Anette Bejder, Jan Fleckner and Just Justesen (1995): Transcriptional regulation of the interferon-gamma inducible tryptophanyl-tRNA synthetase includes alternative splicing. *J. Biol. Chem.*, **270**, 397-403.

Jan Fleckner, Pia M. Martensen, Anne B. Tolstrup, Niels O. Kjeldgaard and Just Justesen: Differential regulation of the human, interferon inducible tryptophanyl-tRNA synthetase by various cytokines in cell lines. *Cytokine*, **7**, 70-77.

Anne Tolstrup, Peter Hokland, Bendt Nielsen, Just Justesen and Marianne Hokland (1993): Expression and regulation of an interferon-alpha-inducible membrane protein p106 on human hematopoietic cells. *J. Interferon Res.* **13**, 433-441.

Jan Fleckner, Anne Tolstrup, Marianne Hokland and Just Justesen: Expression studies of the human interferon-induced tryptophanyl-tRNA synthetase (γ 2) mRNA in various cell types. *J. Interferon Res.*, sup. 1, 1992. s85.

Anne Tolstrup, Nick Hoogenrad, Marianne Hokland and Just Justesen: Characterization of an interferon- α inducible membranprotein, p106. *J. Interferon Res.*, sup. 1, 1991. s158.

Patents

Anne B. Tolstrup, Lars S. Nielsen, Dietmar Weilguny, Christian Müller, Finn C. Wiberg, Jonas H. Graversen. Methods for manufacturing a polyclonal protein. Application WO 2009/129814

Anne B. Tolstrup, Johan Lantto, Finn C. Wiberg and Lars S. Nielsen: Methods for recombinant manufacturing of anti-RSV antibodies. Application WO 2009/030237